Home > Riviste > Minerva Biotecnologica > Fascicoli precedenti > Minerva Biotecnologica 2018 March;30(1) > Minerva Biotecnologica 2018 March;30(1):36-40

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

MINERVA BIOTECNOLOGICA

Rivista di Biologia Molecolare e Biotecnologie


Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,25


eTOC

 

REVIEW  FREEfree


Minerva Biotecnologica 2018 March;30(1):36-40

DOI: 10.23736/S1120-4826.17.02337-0

Copyright © 2017 EDIZIONI MINERVA MEDICA

lingua: Inglese

Adiponectin in hepatology

Ludovico ABENAVOLI 1 , Luigi BOCCUTO 2, 3, Mario MASARONE 4, Rinaldo PELLICANO 5, Marcello PERSICO 4

1 Department of Health Sciences, University “Magna Græcia”, Catanzaro, Italy; 2 Greenwood Genetic Center, Greenwood, SC, USA; 3 Clemson University School of Health Research, Clemson, SC, USA; 4 Unit of Internal Medicine and Hepatology, University of Salerno, Salerno, Italy; 5 Unit of Gastroenterology and Hepatology, Molinette Hospital, Turin, Italy


PDF  


Adiponectin is a protective adipocytokine, involved in the regulation of glucose and lipid metabolism, produced by adipocytes. Adiponectin levels are inversely related to insulin resistance and are lower in obese subjects and in patients with insulin resistance. The hepato-protective effects of adiponectin are largely mediated by the coordination of multiple signalling pathways, leading to enhanced fat oxidation, reduced lipid synthesis and prevention of hepatic steatosis. Literature recently highlighted the role played by adiponectin in the development and progression of liver diseases, in particular non-alcoholic fatty liver disease and chronic hepatitis C. In this context, genetic predisposition influences the evolution of hepatic injury. Adiponectin and its pathways are promising candidates for future development in both the pharmacotherapy and the prediction of liver and metabolic diseases.


KEY WORDS: Cytokines - Insulin resistance - Liver diseases - Non-alcoholic fatty liver disease - Hepatitis C, chronic

inizio pagina

Publication History

Issue published online: December 6, 2017
Manuscript accepted: August 28, 2017
Manuscript received: August 23, 2017

Per citare questo articolo

Abenavoli L, Boccuto L, Masarone M, Pellicano R, Persico M. Adiponectin in hepatology. Minerva Biotec 2018;30:36-40.DOI: 10.23736/S1120-4826.17.02337-0

Corresponding author e-mail

l.abenavoli@unicz.it